ACOT8

Across TCGA pan-cancer cohorts, ACOT8 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACOT8 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ACOT8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACOT8 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, LUSC, and ACC are the cancer types where ACOT8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.031	0.743	<.001	12	view →
ACC	OS	Median	All	0.147	0.685	.018	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.250	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACOT8–STAD (OS)

Open the STAD breakdown →